Clinical trials: Aspergillosis Invasive
Posaconazole, Pharmacokinetics
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
- Conditions
- Posaconazole, Pharmacokinetics, Invasive Candidiases, Invasive Aspergillosis
- Trial name
- POPULAR (NCT03717623)
- Testing
- Posaconazole pharmacokinetics
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Melbourne Health
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Influenza With Pneumonia, Invasive Pulmonary Aspergillosis
Influenza Associated Aspergillosis In-depth Investigation
This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU.
- Trial name
- PIAS (NCT03748069)
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Candidemia, Aspergillosis Invasive
Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)
Invasive fungal infections (IFI) are a major concern for immunocompromised or vulnerable patients. Associated mortality is significant and depends on the timeliness of diagnostic and therapeutic management.
- Conditions
- Candidemia, Aspergillosis Invasive, Pneumocystosis; Pneumonia (Etiology), IFI
- Trial name
- NCT07272915
- Testing
- Beta-1,3/1,6-D-Glucan
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Central Hospital, Nancy, France
Invasive Aspergillosis
F901318 Single Ascending Dose Study in Healthy Male Volunteers
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
- Trial name
- NCT02142153
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Aspergillosis Invasive
Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction
Liposomal amphotericin B is an antifungal agent commonly used to treat invasive aspergillosis, a severe fungal infection associated with high mortality in critically ill patients.
- Trial name
- NCT07337720
- Testing
- LIposomal amphotericin B (L-AmB) treatment
- Volunteers
- 40 people
- Sponsor
- Southeast University, China
Invasive Aspergillosis
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
Concentrations of voriconazole in pulmonary epithelial lining fluid and in serum are compared after inhalation of 40 mg voriconazole b.i.d.
- Trial name
- NCT02396225
- Testing
- Voriconazole
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University of Aarhus
Infection, Pulmonary Complications
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with…
- Trial name
- NCT00003031
- Testing
- amphotericin B deoxycholate, voriconazole
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 212 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
Invasive Aspergillosis (IA) is a very serious fungal infection. Hematological patients are the most affected group. IA has a very high morbimortality due to its rapid progression and because it is very difficult to be early…
- Trial name
- NCT01128907
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Aspergillosis
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
- Trial name
- NCT00047827
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Astellas Pharma Inc
Invasive Fungal Infection
Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
The pharmacokinetics of caspofungin are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine caspofungin concentrations in 20 ICU patients, who will get caspofungin as standard…
- Trial name
- CASCADE (NCT01533558)
- Testing
- caspofungin
- Where
- 4 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Aplastic Anemia, Leukemia, Myeloid, Acute
King's Invasive Aspergillosis Study II
Invasive fungal disease (IFD) is an important cause of mortality and morbidity in patients undergoing intensive chemotherapy or transplantation.
- Conditions
- Aplastic Anemia, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Bone Marrow Transplantation
- Trial name
- NCT02875743
- Testing
- Posaconazole
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- King's College Hospital NHS Trust
Invasive Fungal Infections
Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.
In the context of screening for infectious fungal diseases in patients with malignant haemopathy, and particularly patients with acute leukaemia, the investigator aims to evaluate the performance of an already commercialized but…
- Trial name
- BETA GLUCAN (NCT02851680)
- Testing
- blood samples
- Where
- France
- Volunteers
- 476 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Invasive Aspergillosis
Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole
To evaluate the drug-drug interaction between rifampicin and voriconazole according to CYP2C19 genotype quantitatively following a single oral administration of 200 mg voriconazole
- Trial name
- NCT01080651
- Testing
- Voriconazole
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis, Candidiasis
Voriconazole to Prevent Systemic Fungal Infections in Children
This study will examine how children's bodies metabolize and eliminate the anti-fungal drug voriconazole. The results will yield information needed to make recommendations for safe and effective dosing of the drug in children.
- Conditions
- Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
- Trial name
- NCT00005912
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Immunocompromised Host, Invasive Pulmonary Fungal Infection
Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis
Background: Fungal infections of the lung (pneumonia) can be caused by molds, such as Aspergillus and Zygomycetes, but these causes are often difficult for a doctor to diagnose.
- Conditions
- Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
- Trial name
- NCT00923832
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Aspergillosis/Blood, Aspergillosis/Invasive
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.
- Trial name
- NCT00423163
- Testing
- micafungin, voriconazole
- Where
- 44 sites in United States
- Sponsor
- Astellas Pharma Inc